Buchynska Lyubov, Brieieva Olga, Glushchenko Nadiia, Vorobyova Ludmila, Bilyk Olena
R,E, Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine.
BMC Cancer. 2014 Oct 15;14:765. doi: 10.1186/1471-2407-14-765.
Individual susceptibility to endogenous and/or exogenous DNA damage depends on DNA repair efficiency and can be evaluated using the comet assay with bleomycin as genotoxic agent. The aim of the study was to evaluate baseline and bleomycin-induced DNA damage and DNA repair capacity in peripheral blood lymphocytes (PBLs) of endometrial cancer (EC) patients considering a family history of cancer.
DNA damage was analyzed in PBLs of 45 EC patients compared to a control group of 10 healthy women, using the comet assay. The level of DNA damage was determined by the% tail DNA.
The level of baseline DNA damage in PBLs of EC patients was significantly higher (% DNA in tail 9.31 ± 15.32) than in healthy women (% DNA in tail 3.41 ± 4.71) (P <0.01). PBLs of EC patients repaired less bleomycin-induced DNA damage (removed% DNA in tail 63.94 ± 20.92) than PBLs of healthy individuals (removed% DNA in tail 80.24 ± 3.03) (P <0.001). Efficiency of DNA repair in PBLs of EC patients depended on the family history of cancer. The amount of restored damaged DNA was significantly lower (removed% DNA in tail 36.24 ± 14.05%) in EC patients with a family history of cancer compared to patients with sporadic EC (removed% DNA in tail 64.91 ± 19.36%) (P <0.004).
Lymphocytes of EC patients are characterized by an increased basal level of DNA damage as well as deficiency in DNA repair. DNA repair is less efficient in PBLs of EC patients with a family history of cancer compared to patients with sporadic cancer.
个体对内源性和/或外源性DNA损伤的易感性取决于DNA修复效率，可通过以博来霉素作为基因毒性剂的彗星试验进行评估。本研究的目的是考虑癌症家族史，评估子宫内膜癌（EC）患者外周血淋巴细胞（PBL）中的基线和博来霉素诱导的DNA损伤以及DNA修复能力。
使用彗星试验分析了45例EC患者的PBL中的DNA损伤，并与10名健康女性的对照组进行比较。DNA损伤水平通过尾DNA百分比来确定。
EC患者PBL中的基线DNA损伤水平（尾DNA中的DNA百分比为9.31±15.32）显著高于健康女性（尾DNA中的DNA百分比为3.41±4.71）（P<0.01）。与健康个体的PBL相比，EC患者的PBL修复博来霉素诱导的DNA损伤较少（去除尾DNA中的DNA百分比为63.94±20.92）（去除尾DNA中的DNA百分比为80.24±3.03）（P<0.001）。EC患者PBL中的DNA修复效率取决于癌症家族史。与散发性EC患者（去除尾DNA中的DNA百分比为64.91±19.36%）相比，有癌症家族史的EC患者修复受损DNA的量显著更低（去除尾DNA中的DNA百分比为36.24±14.05%）（P<0.004）。
EC患者的淋巴细胞具有DNA损伤基础水平升高以及DNA修复缺陷的特征。与散发性癌症患者相比，有癌症家族史的EC患者的PBL中DNA修复效率较低。
